Abbott Laboratories filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

April 25, 2025

Date of Report (Date of earliest event reported)

ABBOTT LABORATORIES

(Exact name of registrant as specified in charter)

 

 

Illinois		1-2189		36-0698440
(State or other Jurisdiction		(Commission File Number)		(IRS Employer
of Incorporation)				Identification No.)

 

 

100 Abbott Park Road

Abbott Park, Illinois 60064-6400

(Address of principal executive offices)(Zip Code)

 

Registrant’s telephone number, including area code:  (224) 667-6100

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨        Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨        Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨        Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨        Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities Registered Pursuant to Section 12(b) of the Act:

 

Title of Each Class	Trading Symbol(s)	Name of Each Exchange  on Which Registered
Common Shares, Without Par Value	ABT	New York Stock Exchange Chicago Stock Exchange, Inc.

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company  ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

 

 

Item 5.07 — Submission of Matters to a Vote of Security Holders.

 

Abbott held its Annual Meeting of Shareholders on April 25, 2025. The following is a summary of the matters voted on at that meeting.

 

(1)

The shareholders elected Abbott’s entire Board of Directors. The persons elected to Abbott’s Board of Directors and the number of shares cast for, the number against, the number abstaining, and the number of broker non-votes, with respect to each of these persons, were as follows:

 

Name		Votes For				Votes Against				Abstain				Broker Non-Votes
Robert J. Alpern, M.D.			1,327,438,854				33,059,124				1,692,999				172,532,563
Claire Babineaux-Fontenot			1,353,692,234				6,825,428				1,673,315				172,532,563
Sally E. Blount, Ph.D.			1,336,357,728				23,419,311				2,413,938				172,532,563
Robert B. Ford			1,264,478,626				91,618,170				6,094,181				172,532,563
Paola Gonzalez			1,354,420,876				5,453,437				2,316,664				172,532,563
Michelle A. Kumbier			1,351,012,042				9,433,083				1,745,852				172,532,563
Darren W. McDew			1,350,972,305				8,767,072				2,451,601				172,532,563
Nancy McKinstry			1,116,607,201				243,925,809				1,657,967				172,532,563
Michael G. O’Grady			1,333,186,431				27,251,169				1,753,377				172,532,563
Michael F. Roman			1,344,216,165				16,199,533				1,775,279				172,532,563
Daniel J. Starks			1,305,438,905				55,076,532				1,675,540				172,532,563
John G. Stratton			1,187,966,267				172,531,567				1,693,143				172,532,563

 

(2)

The shareholders ratified the appointment of Ernst & Young LLP as Abbott’s auditors. The number of shares cast in favor of the ratification of Ernst & Young LLP, the number against, the number abstaining, and the number of broker non-votes were as follows:

 

For				Against				Abstain				Broker Non-Votes
	1,495,642,212				36,586,494				2,494,834				0

 

(3)

The shareholders approved the compensation of Abbott’s named executive officers listed in the proxy statement for the Annual Meeting, with 89.90 percent of the votes cast voting “For” the proposal. The shareholder vote is advisory and non-binding. The number of shares cast in favor of approval, the number against, the number abstaining, and the number of broker non-votes were as follows:

 

For				Against				Abstain				Broker Non-Votes
	1,224,503,868				130,699,445				6,987,664				172,532,563

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

	ABBOTT LABORATORIES
Date: April 28, 2025	By:	/s/ PHILIP P. BOUDREAU
		Philip P. Boudreau
		Executive Vice President, Finance
		and Chief Financial Officer